JP2008537673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008537673A5 JP2008537673A5 JP2007553371A JP2007553371A JP2008537673A5 JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5 JP 2007553371 A JP2007553371 A JP 2007553371A JP 2007553371 A JP2007553371 A JP 2007553371A JP 2008537673 A5 JP2008537673 A5 JP 2008537673A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ephb2
- seq
- hvr
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64854105P | 2005-01-31 | 2005-01-31 | |
| US75684406P | 2006-01-05 | 2006-01-05 | |
| PCT/US2006/003502 WO2006083936A2 (en) | 2005-01-31 | 2006-01-31 | Anti-ephb2 antibodies and methods using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008537673A JP2008537673A (ja) | 2008-09-25 |
| JP2008537673A5 true JP2008537673A5 (enExample) | 2009-02-26 |
Family
ID=36341431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553371A Pending JP2008537673A (ja) | 2005-01-31 | 2006-01-31 | 抗ｅｐｈｂ２抗体とその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7767205B2 (enExample) |
| EP (1) | EP1844076A2 (enExample) |
| JP (1) | JP2008537673A (enExample) |
| AU (1) | AU2006210837B2 (enExample) |
| CA (1) | CA2594636A1 (enExample) |
| NZ (1) | NZ556317A (enExample) |
| WO (1) | WO2006083936A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Ｎ末端にアミノ安息香酸単位を有するオーリスタチン |
| WO2006074392A2 (en) * | 2005-01-06 | 2006-07-13 | Genentech, Inc. | Cancer prognostic, diagnostic and treatment methods |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CN101626784B (zh) * | 2006-08-31 | 2013-07-17 | 作为康可信托公司受托人的A.C.N.135493391股份有限公司 | 利用包含抗体的组合物治疗和/或预防非传染性医学病症 |
| ES2528922T3 (es) | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| ATE543835T1 (de) | 2007-07-16 | 2012-02-15 | Genentech Inc | Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren |
| US20090309617A1 (en) * | 2007-08-24 | 2009-12-17 | Ye Fang | Biosensor antibody functional mapping |
| PT2247620T (pt) | 2008-01-31 | 2016-08-23 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| NZ599773A (en) | 2009-11-07 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| EP3925627A1 (en) | 2012-05-15 | 2021-12-22 | Concortis Biosystems, Corp | Drug-conjugates and uses thereof |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| EP3057610B1 (en) | 2013-10-15 | 2021-09-22 | Sorrento Therapeutics, Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| CA2935532A1 (en) * | 2014-02-06 | 2015-08-13 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences |
| DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
| JP6871858B2 (ja) | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 抗体薬物コンジュゲート |
| WO2017089606A1 (en) * | 2015-11-26 | 2017-06-01 | Kotter Mark Reinhard | Therapy to increase remyelination |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| TWI852735B (zh) | 2015-12-04 | 2024-08-11 | 美商思進公司 | 四級胺化妥布賴森(tubulysin)化合物之結合物 |
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| US11046782B2 (en) | 2016-03-30 | 2021-06-29 | Musc Foundation For Research Development | Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination |
| US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
| WO2021255741A1 (en) * | 2020-06-17 | 2021-12-23 | 4C Biomed Services Ltd. | Ephb2 antibody and use thereof in combination therapy |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| CA2429460A1 (en) * | 2000-11-20 | 2002-05-23 | California Institute Of Technology | Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| KR100576674B1 (ko) * | 2001-06-20 | 2006-05-10 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| EP1600459A3 (en) * | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| WO2004044218A2 (en) * | 2002-11-05 | 2004-05-27 | The Regents Of The University Of California | Methods and materials for examining pathways associated with glioblastoma progression |
| EP3434275A1 (en) * | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| WO2005101017A1 (en) * | 2004-04-07 | 2005-10-27 | Genentech, Inc. | Mass spectrometry of antibody conjugates |
| WO2006074392A2 (en) * | 2005-01-06 | 2006-07-13 | Genentech, Inc. | Cancer prognostic, diagnostic and treatment methods |
-
2006
- 2006-01-31 AU AU2006210837A patent/AU2006210837B2/en not_active Ceased
- 2006-01-31 JP JP2007553371A patent/JP2008537673A/ja active Pending
- 2006-01-31 EP EP06720045A patent/EP1844076A2/en not_active Ceased
- 2006-01-31 CA CA002594636A patent/CA2594636A1/en not_active Abandoned
- 2006-01-31 WO PCT/US2006/003502 patent/WO2006083936A2/en not_active Ceased
- 2006-01-31 NZ NZ556317A patent/NZ556317A/en not_active IP Right Cessation
-
2007
- 2007-07-31 US US11/831,787 patent/US7767205B2/en not_active Expired - Fee Related
-
2010
- 2010-06-08 US US12/796,496 patent/US20100278842A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546780A5 (enExample) | ||
| RU2423382C1 (ru) | Композиции и способы диагностики и лечения опухоли | |
| JP2014509835A5 (enExample) | ||
| CN103517719B (zh) | 抗体-药物缀合物 | |
| JP7850455B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| JP2013056896A5 (enExample) | ||
| JP6764873B2 (ja) | Ｆｌｔ３タンパク質に結合する抗体薬物複合体（ａｄｃ） | |
| US10052382B2 (en) | Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides | |
| JP2008529497A5 (enExample) | ||
| JP2018534933A5 (enExample) | ||
| JP2006507013A5 (enExample) | ||
| IL290591B2 (en) | Antibody drug preparations (ADC) that bind to 191P4D12 proteins | |
| JP2017522861A5 (enExample) | ||
| JP2014520088A5 (enExample) | ||
| JP2010504755A5 (enExample) | ||
| JP2014524902A5 (enExample) | ||
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| JP2014531201A5 (enExample) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| RU2012112340A (ru) | Гуманизированные моноклональные антитела к сеа с созревшей аффинностью | |
| JP2010535713A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2020522280A5 (enExample) | ||
| JP2019205480A5 (enExample) |